Evidence map›Paper›PMID 40635105›Full record

ArticleInfectious diseases of poverty2025

Evaluating the effectiveness of mass drug administration on lymphatic filariasis transmission and assessment of post-mass drug administration surveillance in Nigeria's Federal Capital Territory.

Juliana Ajuma Amanyi-Enegela, Joseph Kumbur, Faizah Okunade, Donald Ashikeni, Rinpan Ishaya, Girija Sankar, William Enan Adamani, Moses Aderogba, Louise Makau-Barasa, Achai Emmanuel and 3 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Living with Filariasis: Unseen Struggles of a Neglected Disease.The Yale journal of biology and medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juliana Ajuma Amanyi-EnegelaCBM Christian Blind Mission, Wellington house, Cambridge, UK. Juliana.amanyi-enegela@cbm.org.ORCID http://orcid.org/0000-0002-2565-4735
Joseph KumburCBM Christian Blind Mission Okemesi Crescent Garki 2, Abuja, Nigeria.
Faizah OkunadeCBM Christian Blind Mission Okemesi Crescent Garki 2, Abuja, Nigeria.
Donald AshikeniCBM Christian Blind Mission Okemesi Crescent Garki 2, Abuja, Nigeria.
Rinpan IshayaHealth and Development Support Programme (HANDS), Jos, Nigeria.
Girija SankarCBM Christian Blind Mission, Wellington house, Cambridge, UK.
William Enan AdamaniCBM Christian Blind Mission Okemesi Crescent Garki 2, Abuja, Nigeria.
Moses AderogbaThe END Fund, New York, USA.
Louise Makau-BarasaThe END Fund, New York, USA.
Achai EmmanuelHealth and Development Support Programme (HANDS), Jos, Nigeria.
Bosede Eunice OgundipeDepartment of Public Health, Federal Capital Territory Administration, Abuja, Nigeria.
Chinwe OkoyeNational Lymphatic Filariasis Elimination Programme, Neglected Tropical Diseases, Public Health Department, Federal Ministry of Health, Abuja, Nigeria.
Babar QureshiCBM Christian Blind Mission, Wellington house, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNigeria's Federal Capital Territory (FCT) launched annual mass drug administration (MDA) in its four lymphatic filariasis (LF)-endemic councils in 2011, achieving sustained high coverage and pre-transmission assessment survey success. This study aimed to confirm transmission interruption in Bwari and Gwagwalada and to evaluate post-MDA surveillance efficacy in Abaji and Kuje.

methodsTransmission Assessment Surveys (TAS) were systematically conducted in four distinct evaluation units (EUs) within the FCT. TAS 1 was carried out in Bwari and Gwagwalada EUs that had recently achieved pre-TAS thresholds indicating potential interruption of transmission, whereas TAS 2 was conducted in Abaji and Kuje EUs, where MDA had been discontinued since 2021 following successful TAS 1 evaluations. Abbott Filarial Test Strips (FTS) were employed to test children aged 6-7 years attending selected schools. Data collection adhered to standardized WHO guidelines, utilizing both paper-based and electronic data-capture tools to enhance accuracy and reduce human error.

resultsA total of 6,448 children participated in surveys across the four EUs, with gender distribution closely balanced (53% male, 47% female). In TAS 1 (Bwari and Gwagwalada), no LF-positive cases were identified well below the WHO-defined critical cutoff of 18 cases. In TAS 2 (Abaji and Kuje), a single LF-positive case was detected in Abaji, still below the critical threshold. Participant refusal rates were minimal, reflecting strong community support and engagement.

conclusionsThe findings provide compelling evidence of significant progress toward LF elimination in Nigeria's FCT; however, the single positive case in Abaji underscores the continued importance of vigilant surveillance and integrated vector-management strategies to maintain elimination status and guard against residual transmission.

Indexed as

Elephantiasis, FilarialFilaricidesMass Drug AdministrationAnimalsChildFemaleHumansMaleNigeriaWuchereria bancroftiFilaricidesAssessmentEliminationLymphatic filariasisMass drug administrationNigeriaSub-Saharan AfricaSurveillanceTransmission

Identifiers

PMID40635105
PMCPMC12239499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.